ArticleMolecules (Basel, Switzerland)2025
Selective Cytotoxicity of Ochratoxin A: Pro-Apoptotic Effects on Healthy Immune Cells Compared to Leukemia Cells.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ochratoxin A (OTA) is a widespread mycotoxin with documented nephrotoxic, hepatotoxic, immunotoxic, and carcinogenic effects, while its role in hematological malignancies and immune cells remains insufficiently defined. This study examined the cytotoxic and pro-apoptotic OTA activity in three human leukemia cell lines (CCRF-CEM, K-562, HL-60) and in peripheral blood mononuclear cells (PBMCs) from healthy donors. Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and trypan blue assays, mitochondrial membrane potential (ΔΨM) was assessed with JC-1 dye, caspase-3/7 activity was measured by flow cytometry, and the expression of apoptosis-related genes was analyzed by RT-qPCR. OTA did not significantly affect viability, mitochondrial function, or caspase activity in leukemia cell lines, suggesting relative resistance to OTA-induced apoptosis. In contrast, PBMCs exhibited clear dose- and time-dependent sensitivity, manifested by reduced viability, ΔΨM, caspase-3/7 activation, and transcriptional changes consistent with intrinsic apoptosis, including decreased BCL-2 (anti-apoptotic) and increased BAX (pro-apoptotic), APAF1 (apoptosome component), CASP3, and CASP9 (executioner and initiator caspases) expression. These findings demonstrate that OTA selectively targets healthy immune cells rather than leukemia cells, highlighting its pronounced immunotoxic risk and the importance of caution when considering its effect in a hematological context. Although limited to in vitro models, this study underscores the necessity of further research to clarify the molecular basis of differential OTA sensitivity and its contribution to immunosuppression and hematological disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.